Abstract

W
During her term as editor (1999 – 2009) Dr. Hilman, also a pediatric allergist-immunologist, promoted the Journal as a venue for subspecialty fellows to showcase their research. This trend brought research from major university programs throughout the United States. In 2009 Dr. Harold F. Farber, a pediatric pulmonologist from Texas Children's Hospital at Baylor became the new Editor-in-Chief. Emphasizing the Journal's commitment to publishing articles in both allergy/immunology and pulmonology he lobbied to change the name to Pediatric Allergy, Immunology and Pulmonology. This became official in October of 2010. Dr. Farber brought expert reviews, pro-con debates, and case reports to the Journal, expanding the reach of his predecessors. He continues to work with us as Senior Editor.
In 2013 I had the privilege of joining Pediatric Allergy, Immunology and Pulmonology as its new Editor-in-Chief. With the support of our publisher and our editorial board, three section editors were added (covering the areas of Pediatric Radiology, Pathology and Laboratory Medicine, and Immunology) to provide a more comprehensive approach to the ever-growing body of knowledge that clinicians need to care for children. A “Pharmacology Update,” under the guidance of Drs. Kathryn Blake and Hengameh Raissy has become a regular and frequently downloaded offering. Our editorial board has contributed original research and reviews and enriched clinical case reports with their expert commentary.
The Journal would like to congratulate the following authors whose articles were the top two most frequently downloaded in 2016:
Kelso, JM, Do Written Asthma Action Plans Improve Outcomes, Pediatric Allergy, Immunology and Pulmonology 2016; 29:2–5.
Schraufnagel, D, Electronic Cigarettes: The Vulnerability of Youth. Pediatric Allergy, Immunology and Pulmonology 2015; 28:2–6.
These articles reflect the mission of Pediatric Allergy, Immunology and Pulmonology to promote understanding and advance the treatment of respiratory, allergic, and immunologic diseases in children while highlighting the developmental implications and impact of disease on children and their families.
The Journal is accessible in 170 countries worldwide, including courtesy access to underdeveloped countries due to our partnership with the World Health Organization's Hinari Access to Research for Health program.
We thank you for your support and confidence. Please continue to send us your original research, comprehensive reviews, and commentaries.
